(Q38179828)

30 August 2017

Alternative splicing in cancer: implications for biology and therapy (English)

1 reference

alternative mRNA splicing, via spliceosome

30 August 2017

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24441040%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

J Chen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24441040%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

20 January 2014

1 reference

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24441040%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24441040%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

1-14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24441040%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24441040%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2013.570

1 June 2020

exact match

0 references

cites work

Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

The spliceosome: design principles of a dynamic RNP machine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Alternative splicing and evolution: diversification, exon definition and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Tissue-specific alternative splicing remodels protein-protein interaction networks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Dynamic transcriptomes during neural differentiation of human embryonic stem cells revealed by short, long, and paired-end sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Functional consequences of developmentally regulated alternative splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Degrade, move, regroup: signaling control of splicing proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Identification of alternatively spliced mRNA variants related to cancers by genome-wide ESTs alignment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Cancer-associated regulation of alternative splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Expression and role of Bcl-xL in human hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

CD95, BIM and T cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Pyruvate kinase type M2 and its role in tumor growth and spreading

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

T antigen is bound to a host protein in SY40-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

The p53 proto-oncogene can act as a suppressor of transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

The first 30 years of p53: growing ever more complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Presence of a potent transcription activating sequence in the p53 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

21 January 2018

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Mdm2 promotes the rapid degradation of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

The p53-mdm-2 autoregulatory feedback loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Immunologically distinct p53 molecules generated by alternative splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

p53 isoforms can regulate p53 transcriptional activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

p53 regulates the transcription of its Delta133p53 isoform through specific response elements contained within the TP53 P2 internal promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Regulation of human p53 activity and cell localization by alternative splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Effects of Δ40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Splice mutations in the p53 gene: case report and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Meta-analysis of BRCA1 and BRCA2 penetrance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Identification of a RING protein that can interact in vivo with the BRCA1 gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

In vitro repression of Brca1-associated RING domain gene, Bard1, induces phenotypic changes in mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Is there more to BARD1 than BRCA1?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Integrative genomics identifies LMO1 as a neuroblastoma oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

A truncated splice variant of human BARD1 that lacks the RING finger and ankyrin repeats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Nuclear-cytoplasmic translocation of BARD1 is linked to its apoptotic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Oncogenic BARD1 isoforms expressed in gynecological cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

BARD1 expression predicts outcome in colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

BARD1: an independent predictor of survival in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

The steroid and thyroid hormone receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Drug insight: role of the androgen receptor in the development and progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Formation of the androgen receptor transcription complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Structural basis of androgen receptor binding to selective androgen response elements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Androgen receptor function is modulated by the tissue-specific AR45 variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Heterodimerization is mainly responsible for the dominant negative activity of amino-terminally truncated rat androgen receptor forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Domains of the Human Androgen Receptor Involved in Steroid Binding, Transcriptional Activation, and Subcellular Localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Molecular basis of androgen insensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Molecular analysis of the androgen-receptor gene in a family with receptor-positive partial androgen insensitivity: an unusual type of intronic mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

hnRNP proteins and the biogenesis of mRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

SR proteins and splicing control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Specific interactions between proteins implicated in splice site selection and regulated alternative splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

The role of U2AF35 and U2AF65 in enhancer-dependent splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Understanding alternative splicing: towards a cellular code

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Modulation of exon skipping and inclusion by heterogeneous nuclear ribonucleoprotein A1 and pre-mRNA splicing factor SF2/ASF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Activation of alpha-tropomyosin exon 2 is regulated by the SR protein 9G8 and heterogeneous nuclear ribonucleoproteins H and F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

The gene encoding the splicing factor SF2/ASF is a proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Downregulation of splicing factor SRSF3 induces p53β, an alternatively spliced isoform of p53 that promotes cellular senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Disturbed expression of splicing factors in renal cancer affects alternative splicing of apoptosis regulators, oncogenes, and tumor suppressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

CD44: from adhesion molecules to signalling regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Exon array analysis reveals neuroblastoma tumors have distinct alternative splicing patterns according to stage and MYCN amplification status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Frequent pathway mutations of splicing machinery in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Identification and characterization of a spinal muscular atrophy-determining gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Spinal muscular atrophy: mechanisms and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. I. Taxonomy, fermentation, isolation and screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

The spliceosome as a target of novel antitumour drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Splicing factor SF3b as a target of the antitumor natural product pladienolide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Comprehensive proteomic analysis of the human spliceosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Exonic splicing enhancer motif recognized by human SC35 under splicing conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Identification of a new class of exonic splicing enhancers by in vivo selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Predictive identification of exonic splicing enhancers in human genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Variation in sequence and organization of splicing regulatory elements in vertebrate genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Discovery and analysis of evolutionarily conserved intronic splicing regulatory elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Intronic splicing enhancers, cognate splicing factors and context-dependent regulation rules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Intron size, abundance, and distribution within untranslated regions of genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Circulating soluble Fas in patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

When mutants gain new powers: news from the mutant p53 field.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FONC.2013.570

31 March 2020

12 December 2020

Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

A novel splice site mutation in the androgen receptor gene results in exon skipping and a non-functional truncated protein.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Complete androgen insensitivity caused by a splice donor site mutation in intron 2 of the human androgen receptor gene resulting in an exon 2-lacking transcript with premature stop-codon and reduced expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

The splicing-factor oncoprotein SF2/ASF activates mTORC1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.570

Herboxidiene, a new herbicidal substance from Streptomyces chromofuscus A7847. Taxonomy, fermentation, isolation, physico-chemical and biological properties

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FONC.2013.570

31 March 2020

12 December 2020

New antitumor substances, FR901463, FR901464 and FR901465. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities

2 references

https://api.crossref.org/works/10.1038%2FONC.2013.570

31 March 2020

12 December 2020

The human tumour suppressor gene p53 is alternatively spliced in normal cells

1 reference

12 December 2020

Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line

1 reference

12 December 2020

Altered expression of heterogenous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas

1 reference

12 December 2020

A unique exonic splicing mutation in the human androgen receptor gene indicates a physiologic relevance of regular androgen receptor transcript variants

1 reference

12 December 2020

Differential splicing of human androgen receptor pre-mRNA in X-linked Reifenstein syndrome, because of a deletion involving a putative branch site

1 reference

12 December 2020

Two internal ribosome entry sites mediate the translation of p53 isoforms.

1 reference

12 December 2020

The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing

1 reference

12 December 2020

Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing

1 reference

12 December 2020

Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia

1 reference

12 December 2020

Alternative splicing of human p53 transcripts

1 reference

12 December 2020

Splicing with inverted order of exons occurs proximal to large introns

1 reference

12 December 2020